Reference
[1] January CT, Wann LS, Calkins H, et al. 2019 Focused update on atrial fibrillation AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation 2019; 139:e125-51.
[2] Ansell J, Hirsh J, Hylek E, et al. American college of chest physicians. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133:160S–98S.
[3] Boom MS, Berghuis EM, Nieuwkerk PT, et al. When do patients prefer a direct oral anticoagulant over a vitamin K antagonist? Neth J Med 2015; 73:368–72.
[4] Brekelmans MPA, Kappelhof M, Nieuwkerk PT, et al. Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism. Neth J Med 2017; 75:50–5.
[5] SAVAYSA® [package insert], Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2020.
[6] Giugliano RP 1, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-104.
[7] Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple Therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015; 65:1619-29.
[8] Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012; 52:119S-25S.
[9] Mikkelsen AP, Lindhardsen J, Lip GYH, et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012; 10:1745-51.
[10] Stacy ZA, Call WB, Hartmann AP, Peters GL, Richter SK. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther 2016; 5:1-18.
[11] Oh YB, Hong KS, Heo JH et al. New oral anticoagulants may be particularly useful for Asian stroke patients. J Stroke 2014; 16:73-80.
[12] LIXIANA® [package insert], Seoul, Korea: Daiichi Sankyo Korea Co., Ltd.; 2020.
[13] Schulman S, Kearon C. Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb Haemost 2005; 3:3692–4.
[14] Ayala C, Croft JB, Greenlund KJ, et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995-1998. Stroke 2002; 33:1197-201.
[15] Wang KL, Lip GY, Lin SJ, Chiang CE. Non-Vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke 2015; 46:2555-61.
[16] Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50:309-15.
[17] Kang J, Park KW, Palmerini T, et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119:49-162.
[18] Yamashita T, Koretsune Y, Yasaka M, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 2012; 76:1840-7.
[19] Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484-8.
[20] Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18:3078-83.
[21] Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med 2018; 7:265-73.
Table 1. Factors associated with bleeding events caused by edoxaban use